Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 90
- Registration Number
- NCT05963490
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Innolake Biopharm
- Target Recruit Count
- 200
- Registration Number
- NCT05955105
- Locations
- 🇨🇳
Shandong Cancer Hospital, JiNan, Shandong, China
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 43
- Registration Number
- NCT05907512
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 124
- Registration Number
- NCT05891080
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-08-29
- Target Recruit Count
- 50
- Registration Number
- NCT05888402
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 53
- Registration Number
- NCT05877573
- Locations
- 🇨🇳
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05861557
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05817201
- Locations
- 🇨🇳
Haihua Yang, Taizhou, Zhejiang, China
🇨🇳Taizhou Enze Medical Center(Group) Enze Hospital, Taizhou, Zhejiang, China
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT05813626
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT05803915
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.